GO:0090312 positive regulation of protein deacetylation: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090312 describes any process that increases the rate, frequency, or extent of protein deacetylation, the enzymatic removal of an acetyl group from a protein amino acid.
• The term is a biological_process branch of the Gene Ontology and is dominated by sirtuin (SIRT1-7) and HDAC-family regulators that are recruited, activated, or stabilized by upstream signals [1,5,6].
• Positive regulation of deacetylation controls transcription, metabolism, DNA repair, and immune signaling by reversing lysine acetylation on histones and non-histone substrates [2,4,8].
• Dysregulated deacetylation is implicated in non-alcoholic steatohepatitis, colorectal cancer, breast cancer, cardiac repair, and T cell memory formation [1,2,3,6,7].
• CRISPR knockout, point-mutation, knock-in, and overexpression models are the standard tools for causally testing deacetylation regulators in these disease contexts [2,3,4].
• Because deacetylation is a dynamic post-translational event, researchers combine CRISPR perturbation with acetylation proteomics, imaging, and functional assays to assign directionality [3,4,6].
Description
GO:0090312, positive regulation of protein deacetylation, is a Gene Ontology biological_process term that captures any cellular activity which increases the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. Protein acetylation is a reversible post-translational modification, and its erasure by deacetylases is a central node in epigenetic and metabolic control. Because deacetylation can activate or repress substrate function depending on context, positive regulators of this process are increasingly studied as therapeutic targets in cancer, metabolic disease, and immunology [1,2,5]. The process is executed by two major enzyme families: the zinc-dependent HDACs and the NAD+-dependent sirtuins (SIRT1-7) [5,6]. Positive regulation occurs when upstream signals increase the expression, activity, or substrate accessibility of these enzymes, for example through AMPK-coupled SENP1-Sirt3 signaling under glucose limitation or through SIRT1/PGC-1alpha/PPARalpha pathway activation by formononetin. These examples show that GO:0090312 is not a single reaction but a regulatory layer that integrates nutrient status, stress, and transcriptional programs [1,6]. For researchers, GO:0090312 matters because it provides a controlled vocabulary for annotating experiments that manipulate deacetylase activity, and because perturbations of this process produce measurable phenotypes in disease models such as colorectal cancer and cardiac injury [2,3,8]. Understanding which genes positively regulate deacetylation, and how, is therefore a prerequisite for rational target selection in epigenetic drug discovery.
positive regulation of protein deacetylation At A Glance
| GO ID | GO:0090312 |
|---|---|
| GO term | positive regulation of protein deacetylation |
| Ontology | biological_process |
| Synonym | positive regulation of protein amino acid deacetylation |
| Major function | Increases the rate, frequency, or extent of removal of acetyl groups from protein amino acids, thereby reversing lysine acetylation on histone and non-histone substrates |
| Representative enzymes | Sirtuins (SIRT1, SIRT2, SIRT3) and HDAC-family deacetylases [1,2,5,6] |
| Upstream activators | Nutrient stress, AMPK signaling, and small-molecule modulators such as formononetin [1,6] |
| Disease relevance | Non-alcoholic steatohepatitis, colorectal cancer, breast cancer, cardiac repair, and T cell memory [1,2,3,6,7] |
| Research methods | CRISPR KO/point-mutation/knock-in/overexpression, acetylation proteomics, imaging, and functional assays [2,3,4] |
What Is GO:0090312?
In plain terms, GO:0090312 describes any process that makes protein deacetylation happen faster, more often, or more completely. Protein deacetylation is the removal of an acetyl group (CH3CO-, derived from acetic acid) from a protein amino acid, and positive regulation of this process includes events that activate, recruit, stabilize, or upregulate the enzymes responsible for that removal. The term is a biological_process in the Gene Ontology and is synonymous with positive regulation of protein amino acid deacetylation.
Why Is positive regulation of protein deacetylation Important in Cell Biology?
Positive regulation of protein deacetylation is important because it is a reversible switch that cells use to translate metabolic and stress signals into changes in gene expression, enzyme activity, and immune function [1,5,6]. When this regulatory layer is perturbed, the consequences are visible in clinically relevant phenotypes, including altered tumor growth, metastasis, DNA repair, and cardiac regeneration [2,3,4,8]. As a result, genes that positively regulate deacetylation are both mechanistic probes and candidate drug targets, and the GO term provides a shared annotation framework for comparing results across laboratories.
• Controls reversible lysine acetylation on histones and non-histone proteins, a core epigenetic and signaling mechanism.
• Integrates nutrient and energy status through NAD+-dependent sirtuins and AMPK-coupled signaling.
• Modulates cancer progression, including colorectal carcinoma growth and metastasis [4,8].
• Shapes antitumor immunity through SIRT2-dependent MLH1 regulation in colorectal cancer models.
• Regulates cardiomyocyte proliferation and cardiac repair via STAT3 acetylation control.
• Supports T cell memory development under glucose limitation through SENP1-Sirt3 signaling.
• Contributes to metabolic disease biology such as non-alcoholic steatohepatitis via SIRT1/PGC-1alpha/PPARalpha.
• Is a validated target space for HDAC inhibitors and epigenetic cancer therapy.
• Provides a controlled vocabulary for annotating deacetylation-regulating experiments in the Gene Ontology.
• Enables cross-study comparison of CRISPR perturbation phenotypes in deacetylation pathways [2,3,4].
What Happens During positive regulation of protein deacetylation?
Signal reception and upstream activation
In simple terms: First, a signal tells the cell to remove acetyl groups more actively.
Positive regulation begins when upstream signals increase the activity or availability of deacetylases. For example, glucose limitation activates AMPK-coupled SENP1-Sirt3 signaling in mitochondria, which promotes deacetylation-dependent T cell memory development. Similarly, formononetin promotes fatty acid beta-oxidation and treats non-alcoholic steatohepatitis through the SIRT1/PGC-1alpha/PPARalpha pathway, illustrating how a small molecule can positively regulate deacetylation.
Recruitment of deacetylases to substrates
In simple terms: Next, the deacetylase enzyme is brought to the protein that needs its acetyl group removed.
Once activated, sirtuins and HDACs are recruited to specific substrates. PTMA controls cardiomyocyte proliferation and cardiac repair by enhancing STAT3 acetylation, demonstrating that the balance of acetylation and deacetylation at a single substrate can drive a regenerative phenotype. In cancer cells, SIRT1 promotes glucolipid metabolic conversion to facilitate tumor development in colorectal carcinoma, showing substrate-level recruitment in a metabolic context.
Catalytic removal of acetyl groups
In simple terms: The enzyme then chemically clips the acetyl group off the protein.
The catalytic step removes an acetyl group (CH3CO-) from a lysine residue. Sirtuins use NAD+ as a cofactor, whereas zinc-dependent HDACs use a metal-ion mechanism. This step is the defining event of protein deacetylation, and positive regulation of the process increases its rate, frequency, or extent.
Downstream substrate and pathway effects
In simple terms: Removing the acetyl group changes what the target protein does.
Deacetylation alters substrate localization, stability, and interaction partners. METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions, so regulators that reverse this acetylation can shift METTL3 behavior. Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models, linking deacetylation to DNA mismatch repair and immune surveillance.
Feedback and pathway integration
In simple terms: Finally, the cell adjusts the system so deacetylation stays balanced.
Positive regulation is embedded in feedback loops. MIR497HG-derived miR-195 and miR-497 mediate tamoxifen resistance via PI3K/AKT signaling in breast cancer, showing that deacetylation regulators intersect with kinase pathways that can feed back on enzyme activity. HDAC inhibitors in cancer therapy further demonstrate that pharmacological perturbation of this balance has therapeutic consequences.
Key Genes Involved in GO:0090312 positive regulation of protein deacetylation
The following genes and proteins are experimentally linked to positive regulation of protein deacetylation or to its downstream substrates in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SIRT1 | NAD+-dependent deacetylase that promotes glucolipid metabolic conversion | Facilitates tumor development in colorectal carcinoma and mediates SIRT1/PGC-1alpha/PPARalpha signaling in NASH [1,8] |
| SIRT2 | Deacetylase whose targeting induces MLH1 deficiency | Boosts antitumor immunity in preclinical colorectal cancer models |
| SIRT3 | Mitochondrial deacetylase activated by AMPK-coupled SENP1 signaling | Supports T cell memory development under glucose limitation |
| SENP1 | Sentrin-specific protease that couples to Sirt3 signaling | Part of the glucose-limitation AMPK-SENP1-Sirt3 axis in T cells |
| AMPK | Energy sensor kinase upstream of Sirt3 activation | Links nutrient stress to positive regulation of deacetylation |
| PGC-1alpha | Transcriptional coactivator downstream of SIRT1 | Mediates formononetin effects on fatty acid beta-oxidation in NASH |
| PPARalpha | Nuclear receptor in the SIRT1/PGC-1alpha/PPARalpha pathway | Effector of deacetylation-driven metabolic reprogramming in NASH |
| STAT3 | Transcription factor regulated by acetylation | PTMA controls cardiomyocyte proliferation and cardiac repair by enhancing STAT3 acetylation |
| PTMA | Prothymosin alpha, regulator of STAT3 acetylation | Controls cardiomyocyte proliferation and cardiac repair |
| METTL3 | RNA methyltransferase regulated by acetylation | Acetylation impedes cancer metastasis via nuclear and cytosolic functions |
| MLH1 | DNA mismatch repair protein affected by SIRT2 targeting | SIRT2 inhibition induces MLH1 deficiency and antitumor immunity |
| HDAC family | Zinc-dependent deacetylases targeted by inhibitors | Central to epigenetic modulation in cancer therapy |
| MIR497HG | Host gene for miR-195 and miR-497 | Derived miRNAs mediate tamoxifen resistance via PI3K/AKT signaling |
| miR-195 | MicroRNA from MIR497HG | Contributes to tamoxifen resistance in breast cancer |
| miR-497 | MicroRNA from MIR497HG | Contributes to tamoxifen resistance in breast cancer |
| PI3K/AKT | Signaling pathway intersecting with deacetylation regulation | Mediates tamoxifen resistance in breast cancer |
How Is positive regulation of protein deacetylation Regulated?
Positive regulation of protein deacetylation is itself regulated at multiple levels. Nutrient status is a major input: glucose limitation activates AMPK-coupled SENP1-Sirt3 signaling in mitochondria, which drives deacetylation-dependent T cell memory development. Small molecules can also act as positive regulators, as shown by formononetin promoting fatty acid beta-oxidation through the SIRT1/PGC-1alpha/PPARalpha pathway in non-alcoholic steatohepatitis. In cancer, SIRT1 promotes glucolipid metabolic conversion to facilitate tumor development, indicating that metabolic reprogramming can reinforce deacetylation activity. Pharmacological modulation with HDAC inhibitors further demonstrates that the pathway is druggable and subject to feedback.
positive regulation of protein deacetylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SIRT1 | Non-alcoholic steatohepatitis and colorectal carcinoma metabolism | SIRT1 knockout or overexpression in hepatocyte and colorectal cancer cell lines [1,8] |
| SIRT2 | Colorectal cancer antitumor immunity and MLH1 deficiency | SIRT2 knockout or point-mutation in colorectal cancer models |
| PTMA/STAT3 | Cardiomyocyte proliferation and cardiac repair | PTMA knockout or STAT3 acetylation-mimic knock-in in cardiomyocytes |
| METTL3 | Cancer metastasis via nuclear and cytosolic functions | METTL3 acetylation-site point mutants in metastasis assays |
| SENP1/Sirt3 | T cell memory development under glucose limitation | SENP1 or Sirt3 knockout T cells in memory differentiation assays |
Cancer progression and metastasis
Positive regulation of protein deacetylation is deeply implicated in cancer. SIRT1 promotes glucolipid metabolic conversion to facilitate tumor development in colorectal carcinoma, and targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models. METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions, so deacetylation regulators can shift metastatic potential. In breast cancer, MIR497HG-derived miR-195 and miR-497 mediate tamoxifen resistance via PI3K/AKT signaling, linking deacetylation-adjacent pathways to endocrine therapy resistance. HDAC inhibitors remain a major therapeutic strategy in cancer.
Metabolic and liver disease
In non-alcoholic steatohepatitis, formononetin promotes fatty acid beta-oxidation to treat disease through the SIRT1/PGC-1alpha/PPARalpha pathway, directly connecting positive regulation of deacetylation to hepatic lipid metabolism. SIRT1-driven glucolipid metabolic conversion in colorectal carcinoma further illustrates how deacetylation regulators reshape cellular metabolism in disease.
Cardiac repair and regeneration
PTMA controls cardiomyocyte proliferation and cardiac repair by enhancing STAT3 acetylation, showing that the acetylation/deacetylation balance at a single transcription factor can govern regenerative capacity in the heart. This positions positive regulators of deacetylation as candidate modulators of cardiac repair.
Immunity and T cell memory
Glucose limitation activates AMPK-coupled SENP1-Sirt3 signaling in mitochondria for T cell memory development, demonstrating that positive regulation of deacetylation is required for durable immune memory. Targeting SIRT2 to induce MLH1 deficiency and boost antitumor immunity further links deacetylation control to immune surveillance in colorectal cancer models.
From positive regulation of protein deacetylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a deacetylase required for tumor growth? | CRISPR knockout of SIRT1 or SIRT2 in cancer cell lines and xenografts [2,8] |
| Does a specific acetylation site control substrate function? | Point mutation of the acetylated lysine to arginine or glutamine [3,4] |
| Does a disease-associated variant alter deacetylation? | Knock-in of the variant allele in isogenic cell lines |
| Where and when is the deacetylase active? | Tagged knock-in with fluorescent or affinity tag for imaging and proteomics |
| Does increased deacetylase dosage change phenotype? | Overexpression of SIRT1 or SIRT3 in metabolic or immune cells [1,6] |
| Which pathways depend on deacetylation? | CRISPR library screening combined with acetylation proteomics [2,5] |
How to Study the positive regulation of protein deacetylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Acetylome mass spectrometry | Global lysine acetylation changes | Identifying substrates of SIRT1, SIRT2, and HDACs [3,4] |
| CRISPR knockout | Loss-of-function phenotype | Testing requirement for deacetylases in cancer and immunity [2,8] |
| Point mutation | Site-specific acetylation effects | Mapping acetylated lysines on STAT3 or METTL3 [3,4] |
| Knock-in tagging | Protein localization and interactions | Imaging deacetylase dynamics in cells |
| Overexpression | Gain-of-function phenotype | Testing SIRT1 or SIRT3 sufficiency in metabolism [1,6] |
| Metabolic flux assay | Fatty acid beta-oxidation and glucolipid conversion | NASH and colorectal cancer models [1,8] |
| Immune co-culture | Antitumor immunity and MLH1 status | Colorectal cancer SIRT2 studies |
| CRISPR library screening | Pathway-level dependencies | Discovering deacetylation regulators [2,5] |
Acetylation proteomics
Mass spectrometry-based acetylome profiling measures changes in lysine acetylation across the proteome after perturbation of deacetylation regulators. This approach is essential for assigning substrates to positive regulators of deacetylation and for validating CRISPR phenotypes [3,4].
Functional metabolic assays
Because deacetylation controls metabolism, assays such as fatty acid beta-oxidation measurement and glucolipid conversion assays are used to test SIRT1/PGC-1alpha/PPARalpha pathway activity in NASH and cancer models [1,8].
Immunity and DNA repair readouts
MLH1 deficiency and antitumor immunity can be measured by mismatch repair assays and immune cell co-culture after SIRT2 perturbation. T cell memory development under glucose limitation is assessed by differentiation and survival assays in AMPK-SENP1-Sirt3 models.
Cardiac functional and imaging assays
Cardiomyocyte proliferation and cardiac repair are evaluated using proliferation markers, lineage tracing, and functional imaging in PTMA/STAT3 models. Tagged knock-in lines enable live imaging of deacetylase localization.
How CRISPR Can Be Used to Study GO:0090312 positive regulation of protein deacetylation
Knockout
CRISPR knockout of SIRT1, SIRT2, or SIRT3 is used to test whether a deacetylase is required for a phenotype, such as colorectal cancer growth or T cell memory development [2,6,8]. Knockout models provide clean loss-of-function evidence for positive regulation of deacetylation.
Point Mutation
Point mutation of acetylated lysine residues, for example in STAT3 or METTL3, allows researchers to test whether a specific acetylation site mediates the downstream effect [3,4]. This is critical for distinguishing site-specific regulation from global deacetylase activity.
Knock-in
Knock-in of disease-associated variants or tagged alleles enables isogenic comparison and live imaging of deacetylation regulators [3,4]. Tagged knock-in lines are especially useful for tracking substrate localization.
Overexpression
Overexpression of SIRT1 or SIRT3 tests sufficiency of positive regulation of deacetylation in metabolic and immune contexts, such as NASH and T cell memory [1,6]. Combined with knockout, overexpression establishes directionality of the regulatory axis.
How EDITGENE Supports positive regulation of protein deacetylation Research
Researchers studying positive regulation of protein deacetylation-related genes often need to determine whether a candidate gene is causally involved in a disease phenotype, which requires precise genetic models rather than correlative observations. EDITGENE provides the CRISPR tools and bioinformatics support needed to build those models and interpret the resulting acetylation and functional data.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of protein deacetylation research.
Frequently Asked Questions About positive regulation of protein deacetylation
What is GO:0090312 positive regulation of protein deacetylation?
GO:0090312 is a Gene Ontology biological_process term describing any process that increases the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid.
What genes are involved in positive regulation of protein deacetylation?
Key genes include SIRT1, SIRT2, SIRT3, SENP1, AMPK, PGC-1alpha, PPARalpha, PTMA, STAT3, METTL3, MLH1, and HDAC-family enzymes [1,2,3,4,5,6,8].
How is protein deacetylation positively regulated?
Upstream signals such as glucose limitation activate AMPK-coupled SENP1-Sirt3 signaling, and small molecules like formononetin activate the SIRT1/PGC-1alpha/PPARalpha pathway, increasing deacetylase activity [1,6].
Why is positive regulation of protein deacetylation important in cancer?
It controls tumor metabolism, metastasis, DNA repair, and antitumor immunity, as shown by SIRT1 in colorectal carcinoma and SIRT2 targeting in colorectal cancer models [2,4,8].
What diseases are linked to GO:0090312?
Non-alcoholic steatohepatitis, colorectal cancer, breast cancer, cardiac injury, and impaired T cell memory have been linked to deacetylation regulation [1,2,3,6,7].
How do researchers study positive regulation of protein deacetylation?
They use CRISPR knockout, point mutation, knock-in, and overexpression models combined with acetylome proteomics, metabolic assays, and immune readouts [2,3,4,6].
What is the role of sirtuins in protein deacetylation?
Sirtuins are NAD+-dependent deacetylases; SIRT1, SIRT2, and SIRT3 have been shown to regulate metabolism, immunity, and T cell memory in disease models [1,2,6,8].
Can HDAC inhibitors affect positive regulation of protein deacetylation?
HDAC inhibitors modulate deacetylation balance and are used in cancer therapy, making them relevant pharmacological tools for this process.
What experimental models are best for deacetylation research?
Knockout, point-mutation, knock-in, and overexpression cell models, combined with CRISPR library screening, are standard for causal studies [2,3,4,5].
How does EDITGENE support deacetylation research?
EDITGENE provides knockout, point-mutation, knock-in, overexpression, CRISPR library screening, and bioinformatics services for deacetylation-related targets [2,3,4,5].
Conclusion
GO:0090312 positive regulation of protein deacetylation is a central biological_process that integrates nutrient signals, epigenetic control, and disease phenotypes through sirtuins and HDAC-family enzymes [1,5,6]. The cited literature shows that perturbing this process has measurable consequences in cancer, metabolic disease, cardiac repair, and immunity, making it a high-value target space for mechanistic and therapeutic research [2,3,4,8]. By combining precise CRISPR models with acetylome and functional readouts, researchers can move from correlation to causation and identify which positive regulators of deacetylation are worth pursuing as drug targets [2,3,4,5].
References
- 1. Liao J et al.. 2024. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway.. Phytomedicine 124:155285 PMID: 38185065
- 2. Gao Q et al.. 2025. Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models.. Sci Transl Med 17(807):eadv0766 PMID: 40668890
- 3. Liu N et al.. 2025. PTMA controls cardiomyocyte proliferation and cardiac repair by enhancing STAT3 acetylation.. Sci Adv 11(21):eadt9446 PMID: 40408476
- 4. Li Y et al.. 2022. METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions.. Nat Commun 13(1):6350 PMID: 36289222
- 5. Ramaiah MJ et al.. 2021. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.. Life Sci 277:119504 PMID: 33872660
- 6. He J et al.. 2021. Glucose limitation activates AMPK coupled SENP1-Sirt3 signalling in mitochondria for T cell memory development.. Nat Commun 12(1):4371 PMID: 34272364
- 7. Tian Y et al.. 2023. MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer.. Adv Sci (Weinh) 10(12):e2204819 PMID: 36815359
- 8. Wei Z et al.. 2023. SIRT1 promotes glucolipid metabolic conversion to facilitate tumor development in colorectal carcinoma.. Int J Biol Sci 19(6):1925-1940 PMID: 37063423
